Sotirios Tsimikas1, Gordon W Duff2, Peter B Berger3, John Rogus4, Kenneth Huttner4, Paul Clopton5, Emmanuel Brilakis6, Kenneth S Kornman4, Joseph L Witztum7. 1. Division of Cardiovascular Diseases, University of California San Diego, La Jolla, California. Electronic address: stsimikas@ucsd.edu. 2. Division of Genomic Medicine, University of Sheffield, Sheffield, United Kingdom. 3. Department of Cardiology, Geisinger Health System, Danville, Pennsylvania. 4. Interleukin Genetics, Inc., Waltham, Massachusetts. 5. Veterans Affairs Medical Center, San Diego, California. 6. Veterans Affairs North Texas Healthcare System, Dallas, Texas. 7. Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, California.
Abstract
OBJECTIVES: The aim of this study was to assess the influence of pro-inflammatory interleukin (IL)-1 genotype status on the risk for coronary artery disease (CAD), defined as >50% diameter stenosis, and cardiovascular events mediated by oxidized phospholipids (OxPLs) and lipoprotein (Lp) (a). BACKGROUND: OxPLs are pro-inflammatory, circulate on Lp(a), and mediate CAD. Genetic variations in the IL-1 region are associated with increased inflammatory mediators. METHODS: IL-1 genotypes, OxPL on apolipoprotein B-100 (OxPL/apoB), and Lp(a) levels were measured in 499 patients undergoing coronary angiography. The composite genotype termed IL-1(+) was defined by 3 single-nucleotide polymorphisms in the IL-1 gene cluster associated with higher levels of pro-inflammatory cytokines. All other IL-1 genotypes were termed IL-1(-). RESULTS: Among IL-1(+) patients, the highest quartile of OxPL/apoB was significantly associated with a higher risk for CAD compared with the lowest quartile (odds ratio [OR]: 2.84; p = 0.001). This effect was accentuated in patients age ≤60 years (OR: 7.03; p < 0.001). In IL-1(-) patients, OxPL/apoB levels showed no association with CAD. The interaction was significant for OxPL/apoB (OR: 1.99; p = 0.004) and Lp(a) (OR: 1.96; p < 0.001) in the IL-1(+) group versus the IL-1(-) group in patients age ≤60 years but not in those age >60 years. In IL-1(+) patients age ≤60 years, after adjustment for established risk factors, high-sensitivity C-reactive protein, and Lp(a), OxPL/apoB remained an independent predictor of CAD. IL-1(+) patients above the median OxPL/apoB presented to the cardiac catheterization laboratory a mean of 3.9 years earlier (p = 0.002) and had worse 4-year event-free survival (death, myocardial infarction, stroke, and need for revascularization) compared with other groups (p = 0.006). CONCLUSIONS: Our study suggests that IL-1 genotype status can stratify population risk for CAD and cardiovascular events mediated by OxPL. These data suggest a clinically relevant biological link between pro-inflammatory IL-1 genotype, oxidation of phospholipids, Lp(a), and genetic predisposition to CAD and cardiovascular events.
OBJECTIVES: The aim of this study was to assess the influence of pro-inflammatory interleukin (IL)-1 genotype status on the risk for coronary artery disease (CAD), defined as >50% diameter stenosis, and cardiovascular events mediated by oxidized phospholipids (OxPLs) and lipoprotein (Lp) (a). BACKGROUND:OxPLs are pro-inflammatory, circulate on Lp(a), and mediate CAD. Genetic variations in the IL-1 region are associated with increased inflammatory mediators. METHODS:IL-1 genotypes, OxPL on apolipoprotein B-100 (OxPL/apoB), and Lp(a) levels were measured in 499 patients undergoing coronary angiography. The composite genotype termed IL-1(+) was defined by 3 single-nucleotide polymorphisms in the IL-1 gene cluster associated with higher levels of pro-inflammatory cytokines. All other IL-1 genotypes were termed IL-1(-). RESULTS: Among IL-1(+) patients, the highest quartile of OxPL/apoB was significantly associated with a higher risk for CAD compared with the lowest quartile (odds ratio [OR]: 2.84; p = 0.001). This effect was accentuated in patients age ≤60 years (OR: 7.03; p < 0.001). In IL-1(-)patients, OxPL/apoB levels showed no association with CAD. The interaction was significant for OxPL/apoB (OR: 1.99; p = 0.004) and Lp(a) (OR: 1.96; p < 0.001) in the IL-1(+) group versus the IL-1(-) group in patients age ≤60 years but not in those age >60 years. In IL-1(+) patients age ≤60 years, after adjustment for established risk factors, high-sensitivity C-reactive protein, and Lp(a), OxPL/apoB remained an independent predictor of CAD. IL-1(+) patients above the median OxPL/apoB presented to the cardiac catheterization laboratory a mean of 3.9 years earlier (p = 0.002) and had worse 4-year event-free survival (death, myocardial infarction, stroke, and need for revascularization) compared with other groups (p = 0.006). CONCLUSIONS: Our study suggests that IL-1 genotype status can stratify population risk for CAD and cardiovascular events mediated by OxPL. These data suggest a clinically relevant biological link between pro-inflammatory IL-1 genotype, oxidation of phospholipids, Lp(a), and genetic predisposition to CAD and cardiovascular events.
Authors: Casey E Romanoski; Nam Che; Fen Yin; Nguyen Mai; Delila Pouldar; Mete Civelek; Calvin Pan; Sangderk Lee; Ladan Vakili; Wen-Pin Yang; Paul Kayne; Imran N Mungrue; Jesus A Araujo; Judith A Berliner; Aldons J Lusis Journal: Circ Res Date: 2011-07-07 Impact factor: 17.367
Authors: Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger Journal: N Engl J Med Date: 2005-07-07 Impact factor: 91.245
Authors: Yury I Miller; Soo-Ho Choi; Philipp Wiesner; Longhou Fang; Richard Harkewicz; Karsten Hartvigsen; Agnès Boullier; Ayelet Gonen; Cody J Diehl; Xuchu Que; Erica Montano; Peter X Shaw; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum Journal: Circ Res Date: 2011-01-21 Impact factor: 17.367
Authors: José Manuel Fragoso; Hilda Delgadillo; Luis Llorente; Eduardo Chuquiure; Teresa Juárez-Cedillo; Maite Vallejo; Guadalupe Lima; Janette Furuzawa-Carballeda; Marco Antonio Peña-Duque; Marco Antonio Martínez-Ríos; Gilberto Vargas-Alarcón Journal: Immunol Lett Date: 2010-08-13 Impact factor: 3.685
Authors: Sotirios Tsimikas; Ziad Mallat; Philippa J Talmud; John J P Kastelein; Nicholas J Wareham; Manjinder S Sandhu; Elizabeth R Miller; Joelle Benessiano; Alain Tedgui; Joseph L Witztum; Kay-Tee Khaw; S Matthijs Boekholdt Journal: J Am Coll Cardiol Date: 2010-09-14 Impact factor: 24.094
Authors: Enitan D Carrol; Antony Payton; Deborah Payne; Fabio Miyajima; Mas Chaponda; Limangeni A Mankhambo; Daniel L Banda; Elizabeth M Molyneux; Helen Cox; Greg Jacobson; Daniel F Carr; Malcolm E Molyneux; James P Stewart; John P Quinn; C Anthony Hart; William E Ollier Journal: J Immunol Date: 2011-01-19 Impact factor: 5.422
Authors: Olaf Schultz; Frank Oberhauser; Jasemine Saech; Andrea Rubbert-Roth; Moritz Hahn; Wilhelm Krone; Matthias Laudes Journal: PLoS One Date: 2010-12-13 Impact factor: 3.240
Authors: Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar Journal: J Thromb Thrombolysis Date: 2016-07 Impact factor: 2.300
Authors: Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes Journal: Circulation Date: 2016-08-05 Impact factor: 29.690
Authors: Pia R Kamstrup; Ming-Yow Hung; Joseph L Witztum; Sotirios Tsimikas; Børge G Nordestgaard Journal: Arterioscler Thromb Vasc Biol Date: 2017-06-01 Impact factor: 8.311